Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | XBP1 | P17861 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.45 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22201525 | 0.79 | LMNA (0.56) | ADORA2AMEN1KMT2AMAPTLMNA | |
| SCHEMBL13798093 | 0.77 | HTT (0.59) | HTTNPC1RAB9AXBP1NPSR1 | |
| SCHEMBL10505897 | 0.74 | HTT (0.52) | HTTNPC1RAB9AXBP1NPSR1 | |
| SCHEMBL3584983 | 0.72 | KMT2A (0.50) | ADORA2ANPC1RAB9ANPSR1ATM | |
| SCHEMBL7221673 | 0.72 | ADORA2A (0.60) | ADORA2AADORA1LMNATACR3 | |
| SCHEMBL1064852 | 0.72 | CYP1A2 (0.51) | HTTNPC1RAB9AXBP1NPSR1 | |
| SCHEMBL1062734 | 0.72 | TGFBR1 (0.50) | HTTNPC1RAB9AXBP1NPSR1 | |
| SCHEMBL2837651 | 0.71 | ABCG2 (0.54) | ATMMEN1KMT2AMAPTACP1 | |
| SCHEMBL2876724 | 0.71 | ABCG2 (0.53) | ATMMEN1KMT2AACP1PDE5A | |
| SCHEMBL29870133 | 0.71 | ABCG2 (0.54) | ATMMEN1KMT2AMAPTACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061764-B1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | TECHNION RES & DEV FOUNDATION (IL) | 2014-07-02 | — | — | EP | disclosed |
| EP-2061764-B1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | TECHNION RES & DEV FOUNDATION (IL) | 2014-07-02 | — | — | EP | disclosed |
| US-8541428-B2 | Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-09-24 | — | — | US | disclosed |
| US-8541428-B2 | Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-09-24 | — | — | US | disclosed |
| EP-2589597-A2 | Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (PBR) | Technion Research & Development Foundation (IL) | 2013-05-08 | — | — | EP | disclosed |
| EP-2589597-A2 | Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (PBR) | Technion Research & Development Foundation (IL) | 2013-05-08 | — | — | EP | disclosed |
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-02-04 | — | — | US | disclosed |
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-02-04 | — | — | US | disclosed |
| EP-2061764-A1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | Technion Research & Development Foundation LTD. (IL) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008023357-A1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | NQO1, SIRT5, KEAP1 | ADORA2A 975/4885HTT 43/4885NPC1 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.